ACOR ACORDA THERAPEUTICS
Acorda Therapeutics, Inc. (Acorda) is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the central nervous system (CNS). The Company's marketed drug, Zanaflex Capsules, is United States Food and Drug Administration (FDA)-approved for the management of spasticity. Its lead product candidate, Fampridine-SR, is in a Phase III clinical trial for the improvement of walking ability in people with MS. The Company's preclinical programs also target MS and SCI, as well as other CNS disorders, including stroke and traumatic brain injury.
Stock history for ACOR ACORDA THERAPEUTICS
Acorda Therapeutics to Present at the Lazard Capital Markets 5th Annual Healthcare Conference (Business Wire)HAWTHORNE, N.Y.----Acorda Therapeutics, Inc. today announced that Ron Cohen, M.D., President & CEO, will present at the upcoming Lazard Capital Markets 5th Annual Healthcare Conference on Wednesday, November 19, 2008 at 9:00 a.m.
Read 
Acorda Therapeutics to Present at the Piper Jaffray 20th Annual Healthcare Conference (Business Wire)HAWTHORNE, N.Y.----Acorda Therapeutics, Inc. today announced that Ron Cohen, M.D., President & CEO, will present at the upcoming Piper Jaffray Healthcare Conference on Tuesday, December 2, 2008 at 11:30 a.m.
Read
Deutsche Bank: Acorda drug likely to be approved (AP)Deutsche Bank-North America started coverage of Acorda Therapeutics Inc. with a "Buy" rating Tuesday, saying the company's developing neurological drug Fampridine SR will likely get U.S. regulatory approval and could have peak sales of $700 million.
Read
Acorda Therapeutics to Present at RBC Capital Markets Healthcare Conference (Business Wire)HAWTHORNE, N.Y.----Acorda Therapeutics, Inc. today announced that Ron Cohen, M.D., President & CEO, will present at the upcoming RBC Capital Markets Healthcare Conference on Wednesday, December 10, 2008 at 8:00 a.m.
Read
Acorda Therapeutics to Present at the 2008 Deutsche Bank Biotech Boston Confab (Business Wire)HAWTHORNE, N.Y.----Acorda Therapeutics, Inc. today announced that Ron Cohen, M.D., President & CEO, will present at the upcoming Deutsche Bank Biotech Boston Confab on Tuesday, November 11, 2008 at 4:35 p.m.
Read
Acorda Therapeutics to Present at the 27th Annual JPMorgan Healthcare Conference (Business Wire)HAWTHORNE, N.Y.----Acorda Therapeutics, Inc. today announced that Ron Cohen, M.D., President & CEO, will present at the upcoming JPMorgan Healthcare Conference on Monday, January 12, 2009 at 10:30 a.m.
Read
Acorda Therapeutics Names Thomas C. Wessel, M.D., Ph.D., as Chief Medical Officer (Business Wire)HAWTHORNE, N.Y.----Acorda Therapeutics, Inc. today announced that Thomas C. Wessel, M.D., Ph.D., has joined the Company as Chief Medical Officer, reporting to Ron Cohen, M.D., President and CEO.
Read
Acorda Therapeutics Elects John P. Kelley to Board of Directors (Business Wire)HAWTHORNE, N.Y.----Acorda Therapeutics, Inc. today announced that John P. Kelley, President and Chief Operating Officer of The Medicines Company , has been elected to its Board of Directors.
Read
Finance news provided by Yahoo! Finance.
